SecBot SecBot
SECBOTREPLAY Home › Report › APGE

APGE · Apogee Therapeutics completed a public offering of 5,750,000 shares at…

Apogee Therapeutics · PRESS-RELEASE filed Mar 26, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 26, 2026 at 16:01 ET

Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 million in gross proceeds. The capital will support development of its clinical-stage biologics pipeline in inflammatory and immunology indications.

  • Apogee Therapeutics closed an underwritten public offering of 5,750,000 shares of common stock
  • Offering price was $70.00 per share, with full exercise of underwriters' option for 750,000 additional shares
  • Aggregate gross proceeds were approximately $403 million before expenses
  • Proceeds will be used to advance clinical development of Apogee's biologics pipeline, including zumilokibart (APG777) for atopic dermatitis, asthma, and EoE

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access